Biolegend, 304242, FITC anti-human CD45RO Antibody, 100μg

CD45RO is a 180 kD single chain membrane glycoprotein. It is a splice variant of tyrosine phosphatase CD45, lacking the A, B, and C determinants. The CD45RO isoform is expressed on activated and memory T cells, some B cell subsets, activated monocytes/macrophages, and granulocytes. CD45RO enhances both T cell receptor and B cell receptor signaling mediated activation. CD45 and its isoforms non-covalently associate with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1 and CD22. CD45 isoform expression can change in response to cytokines.
100μg
Verified Reactivity: Human
Reported Reactivity: Chimpanzee, Cynomolgus, Common Marmoset
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: IL-2 dependent T cell line, CA1
Formulation: µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.test size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration: µg size: 0.5 mg/mltest size: lot-specific
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)
Application Notes: The UCHL1 antibody is commonly used in combination with antibodies against CD45RA to discern memory and naïve T cells. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections5 and formalin-fixed paraffin-embedded tissue sections4, Western blotting2, and immunoprecipitation3. UCHL1 signal intensity may be reduced in the presence of True-Stain Monocyte Blocker™ (Cat. No. 426102). Clone S19021B is not impacted by Monocyte Blocker and is recommended as an alternative to UCHL1.
Application References(PubMed link indicates BioLegend citation): Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. (FC) Ishii T, et al. 2001. P. Natl. Acad. Sci. USA 98:12138. (WB) Ponsford M, et al. 2001. Clin. Exp. Immunol. 124:315. (IP) Yamada M, et al. 1996. Stroke 27:1155. (IHC) Sakkas LI, et al. 1998. Clin. Diagn. Lab. Immunol. 5:430. (IHC) Baba N, et al. 2010. Int. Immunol. 22:237. PubMed Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed Weiss L, et al. 2010. P. Natl. Acad. Sci. USA 107:10632. PubMed Wu YY, et al. 2007. Infect. Immun. 75:4357. PubMed Mozaffarian N, et al. 2008. Rheumatology 47:1335. PubMed Roque S, et al. 2007. J. Immunol. 178:8028. PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Smith SH, et al. 1986. Immunology 58:63. (Immunogen) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations: Imai H, et al. 2023. iScience. 26:106822. PubMed Li Y, et al. 2022. J Med Virol. 94:3998. PubMed Davé E, et al. 2023. MAbs. 15:2160229. PubMed Zeng W, et al. 2017. Front Immunol. 0.806944444. PubMed Hess NJ, et al. 2020. J Immunol. 205:272. PubMed Shi Z, et al. 2021. Ann Clin Transl Neurol. 8:43. PubMed Elston L, et al. 2020. Br J Haematol. 188:872. PubMed Torres-Ruiz J, et al. 2021. Front Immunol. 12:689966. PubMed Subrahmanyam P, et al. 2014. J Immunol. 193:2096. PubMed Pu X, et al. 2018. J Transl Med. 16:328. PubMed Fang F, et al. 2021. Cell Rep. 37:109981. PubMed Tang J, et al. 2012. Vaccine. 30:1071. PubMed Baba N, et al. 2010. Int Immunol. 1.08125. PubMed Aalam F, et al. 2020. PLoS Pathog. 16:e1008968. PubMed Kim ML, et al. 2021. iScience. 24:103509. PubMed
RRID: AB_314420 (BioLegend Cat. No. 304204) AB_2564159 (BioLegend Cat. No. 304242)
Structure: Tyrosine phosphatases, type I transmembrane, 180 kD (isoform of CD45 containing none of the A, B, or C determinants)
Distribution: Activated and memory T cells, B cell subsets, monocytes, macrophages, granulocytes
Function: Enhances TCR and BCR signaling
Ligand/Receptor: CD22
Cell Type: B cells, Granulocytes, Macrophages, Mesenchymal Stem Cells, Monocytes, T cells, Tregs
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family: CD Molecules
Antigen References: 1. Thomas M. 1989. Annu. Rev. Immunol. 7:339. 2. Trowbridge I, et al. 1994. Annu. Rev. Immunol. 12:85.
Gene ID: 5788
UniProt: View information about CD45RO on UniProt.org
Clone: UCHL1
Regulatory Status: RUO
Workshop: IV N31
Other Names: CD45RO
Isotype: Mouse IgG2a, κ